| Literature DB >> 12021579 |
Otto Mayer1, Jan Filipovský, Milan Hromádka, Vlasta Svobodová, Jaroslav Racek, Otto Mayer1, Pavel Stehlík, Ladislav Trefil, Marta Zárybnická.
Abstract
The aim of the study was to determine whether folic acid treatment in subjects with homocysteinemia would change their coagulation and oxidative status. Thirty-three patients with peripheral vascular disease and 26 elderly subjects with no symptoms of atherosclerosis, all of whom had total homocysteine >20 microM, were treated with folic acid (5 or 10 mg) for 3 months. In the 33 patients with peripheral vascular disease, homocysteine levels decreased from a median of 26.7 microM at baseline to 20.0 microM (p < 0.0001), whereas in the 26 asymptomatic elderly subjects, homocysteine level decreased from 24.4 microM to 18.6 microM (p < 0.0001). Plasma fibrinogen decreased whereas plasminogen and anti-thrombin increased; the differences between pre- and posttreatment values were significant in both patients and healthy subjects. Oxidative status markers showed a shift toward lower oxidative stress. This effect was observed in both study groups. An association of the therapeutic effect with the genetic polymorphism of 5,10-methylenetetrahydrofolate reductase was not detected. Folic acid supplementation to hyperhomocysteinemic subjects resulted in a decrease in total blood homocysteine concentrations; moreover, there was a tendency to reverse the coagulation status and oxidative stress.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12021579 DOI: 10.1097/00005344-200206000-00010
Source DB: PubMed Journal: J Cardiovasc Pharmacol ISSN: 0160-2446 Impact factor: 3.105